Parkinson's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Parkinson's Disease, including details on symptoms, treatment, genetics, medication.

Volume 4 (2007), Issue 9 (September)

1. A case of levodopa-responsive camptocormia associated with advanced Parkinson's disease.
   Nat Clin Pract Neurol, 3(9): 526-30. [Abstract] [Full-text]
2. Epidemiologic studies of environmental exposures in Parkinson's disease.
   J Neurol Sci, 262(1): 37-44. [Abstract] [Full-text]
3. Comparative features of the epidemiology of multiple sclerosis and Parkinson's disease: environmental factors of potential etiological importance.
   J Neurol Sci, 262(1): 54-9. [Abstract] [Full-text]
4. Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study.
   J Neurol Neurosurg Psychiatry, 78(10): 1140-2. [Abstract] [Full-text]
5. Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease.
   J Neurol Neurosurg Psychiatry, 78(10): 1064-8. [Abstract] [Full-text]
6. Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms.
   J Neurol Neurosurg Psychiatry, 78(10): 1097-102. [Abstract] [Full-text]
7. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
   J Neurochem, 103(1): 238-47. [Abstract] [Full-text]
8. Levodopa-induced ocular dyskinesia in Parkinson's disease.
   Eur J Neurol, 14(10): 1124-8. [Abstract] [Full-text]
9. The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease.
   Eur J Neurol, 14(10): 1088-90. [Abstract] [Full-text]
10. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    J Pharmacol Exp Ther, 323(1): 277-84. [Abstract] [Full-text]
11. Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.
    J Pharmacol Exp Ther, 323(1): 318-26. [Abstract] [Full-text]
12. Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study.
    Occup Environ Med, 64(10): 673-80. [Abstract] [Full-text]
13. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study.
    Occup Environ Med, 64(10): 666-72. [Abstract] [Full-text]
14. Calcium, ageing, and neuronal vulnerability in Parkinson's disease.
    Lancet Neurol, 6(10): 933-8. [Abstract] [Full-text]
15. Assessment of the progression of Parkinson's disease: a metabolic network approach.
    Lancet Neurol, 6(10): 926-32. [Abstract] [Full-text]
16. Nicotinic receptors as CNS targets for Parkinson's disease.
    Biochem Pharmacol, 74(8): 1224-34. [Abstract] [Full-text]

© 2004-2008 Parkinson's Disease Research Today. All Rights Reserved.